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Copyright © 200? JCBN Summary It has been reported that levels of soluble intercellular adhesion molecule-1
(ICAM-1) in the blood are elevated in hepatocellular carcinoma patients. In the present study,
serial observations of the localization of ICAM-1 in the liver were made by light and electron
microscopy in rats with carcinogen-induced cancer. Male Fisher rats were given diethylnitro-
samine (DEN) orally in their drinking water. Rats were sacrificed at 6, 8, 12, or 14 weeks after
the start of DEN administration and the liver tissue was collected. ICAM-1 expression in liver
was assessed using indirect immunoperoxidase staining with anti-rat ICAM-1 antibody.
Although ICAM-1 expression by endothelial cells in livers of DEN-treated rats was lower than
in the control group at 8 weeks, it was higher in the membrane and cytoplasm of hepatocytes.
The expression of ICAM-1 in mesenchymal cells was decreased, paralleling development of
cellular atypia, whereas in hepatocyte membranes and cytoplasm it was increased in these
atypia. ICAM-1 was localized to the cytoplasm of cancer cells, but to the membrane of hepa-
tocytes in the treated livers at 14 weeks. Furthermore, the levels of ICAM-1 in mesenchymal
cells tended to be lower in the cancerous area than in the atypical hyperplastic nodule, and
were reduced as the density of cell atypia increased, in comparison to cells in areas without
cancerous nodules. We concluded that ICAM-1 may be influenced the development of cancer
induced in the rat liver by a chemical carcinogen.
Key Words:intracellular adhesion molecule-1 (ICAM-1), rat, Diethylnitrosamine (DEN), cancer,
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Introduction
Intercellular adhesion molecule-1 (ICAM-1) is member
of the immunoglobulin superfamily and a ligand for leuko-
cyte function associated antigen 1 [1–3]. It has been reported
already that levels of soluble(s) ICAM-1 in the blood
correlate with the intensity of intrahepatic fibrosis in human
C-viral chronic hepatitis (CH) or liver cirrhosis (LC) and are
elevated in hepatocellular carcinoma (HCC) [4–6]. Recently,
enhanced expression of ICAM-1 has been reported in human
HCC and ICAM-1 is localized in the cell membrane and
endoplasmic reticulum of the tumour cells [7, 8]. In particular,
it has been reported that ICAM-1 promotes the growth of
residual liver cells, improves delayed hepatic regeneration
in disturbed livers, and inhibits the development of hepatic
fibrogenesis or cirrhosis [9–11]. We have detected already
sICAM-1 in blood and intrahepatic ICAM-1 in patients with
C-viral CH, LC, and HCC [12]. In these studies, levels of
sICAM-1 in blood were significantly higher in patients with
HCC than in chronic hepatitis and LC patients. Furthermore,
we reported that measurement of sICAM-1 levels in bloodS. Matsuoka et al.
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was useful clinically for early diagnosis of HCC and deci-
sions of efficacy of therapy in HCC patients, because
ICAM-1 was expressed in the cancer cells of these patients.
Therefore, in the present study, we made serial observations
of the localization of ICAM-1 in liver by light and electron
microscopy in rats with carcinogen-induced cancer. We
sought to clarify whether ICAM-1 expression also are




Male Wistar rats (200–225 g) were given Diethylnitro-
samine (DEN; 100 mg/litle Sigma Chemical Co., St. Louis,
MO), dissolved in their drinking water, and libitum for up to
14 weeks. Of the DEN-treated rats, 5 were sacrificed at 6
weeks (Rats No. 1 to No. 5), 4 at 8 weeks (Rats No. 6 to No.
9), 5 at 12 weeks (Rats No. 10 to No. 14), and 3 at 14 weeks
(Rats No. 15 to No. 17). The control rats were given water
without DEN, and one was sacrificed at each of weeks 6, 8,
12 and 14. These experimental animals were treated in
accordance with the guidelines of Nihon University (1989).
Histological analysis of liver tissue
Livers were obtained following sacrifice and divided
into two parts. One part was fixed in 10% buffered formalin
and embedded in paraffin and the other used for the detec-
tion of ICAM-1. Each paraffin-embedded specimen was cut
into 3 to 4 micrometer sections, which were stained with
hematoxylin and eosin (HE).
Localization of ICAM-1 in liver
The liver tissue was frozen rapidly with dry ice and
acetone, with OCT compound for embedding, and stored at
−80°C until use. Four micrometer sections were fixed with
acetone and subjected to two sessions of microwave treat-
ment for 30 sec. After 20 min at room temperature, the
ICAM-1 in liver was detected using an indirect immuno-
peroxidase staining method with polyclonal anti-ICAM-1
antibody (1:500 dilution) as the primary antibody and
peroxidase-labeled anti-rabbit Immunoglobulin G (MBL,
Fig. 1. Histological findings in the livers of DEN-treated and control rats. (a) Hepatocyte nuclei are irregular in size and changes in the
staining of the cytoplasm are visible in some animals sacrificed at 6 weeks. (b) Distorted structure of hepatic lobules, and size
variation of hepatocyte nuclei as well as a tendency to basophilic staining is increased further in some animals sacrificed at 6
weeks. (c) In some areas, groups of hepatocytes with strong atypia are present. (d) Marked nodulation observed in each animal
sacrificed at 12 weeks and parts of the nodules are considered to be AH. (e) Small CA observed in all rats except for No. 13. (f)
No histological changes in either control animal sacrificed at 14 weeks (Hematoxylin and eosin staining, original magnification:
a, ×10; b, ×10; c, ×10; d, ×4; e, ×4; f, ×4).ICAM-1 Expression in DEN Rat Liver
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Tokyo, Japan, 1:300 dilution) as the secondary antibody.
This investigation was carried out in animals from the DEN
administration and control groups at 6, 8, 12 and 14 weeks.
The degree of ICAM-1 expression in liver was semiquanti-
tatively classified into 5 grades (none, absent; slight,
presence of only several positive cells in all lobules;
mild, scattered positive cells in several lobules; moderate,
scattered positive cells in all lobules; marked, diffuse posi-
tive cells in all lobules).
For immunoelectron microscopy (IEM) after the 3,3'-
diaminobenzidine (DAB, SIGMA, St. Louis) reaction, the
tissues were incubated with 2.5% glutaraldehyde (NISSIN
EM Co., Ltd., Tokyo, Japan) and 2% osmic acid (NISSIN
EM Co., Ltd.) for 60 min at room temperature, and then
Fig. 2. Localization of ICAM-1 in the livers of rats sacrificed at each time point. Intrahepatic ICAM-1 staining is diffuse and observed
predominantly in the sinusoidal endothelial cells and hepatocyte membranes of the two control animals sacrificed at each time
point (a and b). The intrahepatic ICAM-1 in DEN rats sacrificed at 6 weeks is expressed at moderate levels by endothelial cells
and hepatocyte membranes without cellular atypia and less strongly in the membranes of hepatocytes with cellular atypia (c and
d). The expression of intrahepatic ICAM-1 in DEN rats sacrificed at 8 weeks is moderate in the endothelial cells and hepatocyte
membranes without cellular atypia, and slight to moderate with cellular atypia (e and f). (g) ICAM-1 expressed at higher levels
in hepatocytes with strong atypia located with a map-like distribution than in areas without cellular atypia. (f) Intrahepatic
ICAM-1 in the cancerous region expressed at low levels in the cancer cell membranes of rats sacrificed at 14 weeks
(Counterstained by hematoxylin, original magnification: a, ×4; b, ×20; c, ×4; d, ×10; e, ×4; f, ×20; g, ×4; h, ×20).S. Matsuoka et al.
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embedded in epon 812 (NISSIN EM Co., Ltd.) for 48 h
at 60°C. Ultra thin section were obtained using an
ULTRATOME IIIR (LKB, Bromma, Sweeden) and observed
on a JEM-100C electron microscope (JEOL, Tokyo, Japan).
Sequence analysis of ICAM-1 in the cancerous foci
Parts of the liver, apparently including cancerous regions,
were taken from two rats (Nos. 15 and 16) sacrificed at 14
weeks. The nucleotide sequences of ICAM-1 DNA in the
excised tissues were determined as described below, and
compared to that reported previously [13]. DNA was
extracted from 100 mg of frozen liver using DNAzol (Sanko
Junyaku, Tokyo, Japan) according to the manufacturer’s
instructions. DNA amplification was carried out using
nested PCR, generating a 1769 bp product. The sequences
of the outer primer pair were 5'-CTGCTGCCTGCACTTT
GCCCT-3' [ICAM–s1; sense, nucleotide position (nt) 1–21],
and 5'-GTGTCCAGGTCACGAGTTCAC-3' (ICAM-a1;
antisense, nt 1831–1851), and the sequences of the inner
primer pair were 5'-ACCCGTGCCAGGCCCATGCTG-3'
(ICAM-s2; sense, nt 39–60), and 5'-TTAGGCCTGAGG
CTACAA GTA-3' (ICAM-a2; antisense, nt 1788–1808). The
first round PCR reaction contained 1 µmol of each outer
primer, 1U of Taq DNA polymerase (Boehringer Mannheim,
Mannheim, Germany), 200 µl M of each of the four deoxy-
nucleotides and 1x Taq buffer containing 1.5 mM MgCl2,
and was amplified for 35 cycles of 94°C for 40 s, 55°C for
40 s and 72°C for 150 s. The second round PCR amplified
3 µl of the first PCR product using 1 pico mole of each inner
primer and the same buffer and cycling conditions as in the
first round reaction. The second round PCR products were
sequenced as described by Shibahara et al. [14] using an
ABI model 310 DNA Sequencer.
Results
Histological findings
No cancer lesions were apparent in any animal sacrificed
at 6 weeks. However, hepatocyte nuclei were irregular in
size and changes in the staining of the cytoplasm were
observed in some animals (Fig. 1a). No atypical hyperplastic
areas (AH) and cancerous areas (CA) were found in the
livers of DEN-treated rats sacrificed at 8 weeks. However,
the structure of the hepatic lobules was distorted, and varia-
tions in hepatocyte nuclear dimensions and the tendency to
basophilic staining were increased further (Fig. 1b). Groups
of hepatocytes with strong atypia were observed in some
areas (Fig. 1c). A marked nodulation was observed in
each animal sacrificed at 12 weeks and parts of the nodules
were considered AH (Fig. 1d). In addition, small CA were
observed in all rats, except No. 13 (Fig. 1e). There were no
histological changes in any animals from the control group,
sacrificed at 6, 8, 12 or 14 weeks (Fig. 1f).
Localization of ICAM-1 in the liver
ICAM-1 expression in the liver was diffuse and observed
Table 1. Intrahepatic I CAM-1 expression in Irat livers with DEN Chemostimulated Carcinogenesis.




Hepatocyte Atypical hyperplasia Cancer Cell
Membrane Cytoplasm Membrane Cytoplasm Membrane Cytoplasm
6w 1 modrate none none n.d n.d n.d n.d
2 moderate none none n.d n.d n.d n.d
3 moderate slight none n.d n.d n.d n.d
4 moderate slight none n.d n.d n.d n.d
5 (ct) marked none none n.d n.d n.d n.d
8w 6 moderate none none n.d n.d n.d n.d
7 mild mild none n.d n.d n.d n.d
8 mild mild none n.d n.d n.d n.d
9 (ct) marked none none n.d n.d n.d n.d
12w 10 moderate moderate none slight mild mild mild
11 mild moderate none mild mild mild slight
12 mild moderate none mild mild slight mild
13 mild mild none none none n.d n.d
14 (ct) moderate none none none none none none
14w 15 mild slight none slight slight slight mild
16 mild slight none none slight mild mild
17 (ct) moderate none none none none none noneICAM-1 Expression in DEN Rat Liver
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predominantly in the sinusoidal endothelial cells and mem-
branes of hepatocytes in the one animal of the control group
sacrificed at each time point (Fig. 2a and b). ICAM-1
expression in DEN rat livers at 6 weeks was moderate in the
endothelial cells and slight in the membranes of hepatocytes
with atypia (Fig. 2c and d). However, the levels in both
endothelial cells and hepatocyte membranes were lower
than in control rats sacrificed at 6 weeks (Table 1). ICAM-1
expression in liver endothelial cells of DEN rats sacrificed
at 8 weeks was slight to moderate in areas where the hepato-
cytes were without atypia (Fig. 2e), and only slight in areas
with atypia (Fig. 2f). In particular, ICAM-1 expression was
stronger in membranes of hepatocytes with strong atypia
located in a map-like distribution area, than in hepatocytes
without atypia (Fig. 2g). ICAM-1 expression in CA was
observed in the cytoplasm and membranes of the cancer
cells in rats sacrificed at 12 or 14 weeks (Fig. 2h). The
expression of ICAM-1 by endothelial cells in CA was much
lower than in what were considered to be normal areas of
the same tissue. Moreover, ICAM-1 levels in endothelial
cells tended to be lower in CA than in the AH areas and were
further reduced as the density of atypical hepatocytes
increased, as compared with hepatocytes in non-cancer
areas. On the other hand, the expression of ICAM-1 in cell
membranes and cytoplasm of cancer cells or hepatocytes
with severe atypia was increased compared to hepatocytes
without atypia in non-cancerous areas. In particular, the
degree of expression of ICAM-1 in liver correlated with a
map-like distribution or anisocytosis in irregular regenera-
tion of hepatocytes [15–17].
Ultrastructural findings
Morphology of the tissue sections was studied by electron
microscopy. ICAM-1 was detected in the membranes of
mesenchymal cells and those hepatocytes with seemingly
severe atypia (Fig. 3a). Furthermore, ICAM-1 was observed
in the endoplasmic reticulum (ER) of cancer cells (Fig. 3b).
Sequence analysis
There were no coding changes in 3 clones isolated from
rat no. 15 and another 3 from no. 16 compared to the
consensus sequence [13].
Discussion
In rats with DEN-induced cancer, the pattern of expres-
sion of ICAM-1 in liver differed clearly between hepato-
cytes and endothelial cells in parenchyma without hepato-
cyte atypia and the cancerous area and hepatocytes within
areas of atypia, even in the same liver. The level of endo-
thelial cell ICAM-1 expression decreased as the degree of
cellular atypia increased, whereas, in contrast, it was
increased in hepatocyte membranes. In particular, the
expression of ICAM-1 with a map-like distribution of
irregular regeneration of hepatocytes was higher than in
other areas not showing this pattern. Furthermore, the
expression of ICAM-1 in cell membranes and cytoplasm of
cancer cells in the CA and hepatocytes in the AH areas was
clearly greater than in areas lacking CA and AH. Thus,
ICAM-1 density in cancer cells and hepatocytes with severe
atypia was increased more than in areas without CA or
severe hepatocyte atypia. Therefore, there is a clear distinc-
tion between areas with or without hepatocyte atypia and
CA and AH. Furthermore, the cancer cells themselves
produced the ICAM-1, because it was observed by IEM in
their ER and in hepatocytes within areas of atypia. The role
of ICAM-1 in hepato-carcinogenesis was not clear from the
morphological observations above, but it was possible to
distinguish areas with marked cellular atypia from normal
areas. From these results, we consider that ICAM-1
influenced the development of hepatocyte atypia. Levels of
sICAM-1 are increased parallel to development of F stages
and HCC in type C liver diseases. In the present study, the
expression of ICAM-1 in mesenchymal cells decreased as
Fig. 3. (a) ICAM-1 detected by electron microscopy in the
membranes of infiltrating cells, which seem to be endo-
thelial cells, and in the membranes of hepatocytes
(arrows). (b) ICAM-1 observed in the endplasmic
reticulum (ER; arrows) of cancer cells (CA) (Ultra thin
section EM: a, ×6,000; b, ×12,000).S. Matsuoka et al.
J. Clin. Biochem. Nutr.
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cellular atypia increased. Reciprocally, it increased in the
membrane and cytoplasm of hepatocytes, paralleling the
development of cellular atypia. Furthermore, the ICAM-1
was present in both the cell membrane and cytoplasm of
cancer cells. The degree of expression of ICAM-1 in
mesenchymal cells in CA was clearly decreased compared
to the non cancerous areas of the same rat liver. Therefore,
the reason that sICAM-1 concentration in humans is
reported to increase as F stages or HCC develop is suggested
to be that ICAM-1 secretion by hepatocytes with atypia or
by cancer cells is increased.
In addition, we analyzed the gene sequence of ICAM-1
from parts of livers including CA two different rats (Nos. 15
and 16) sacrificed at 14 weeks. The nucleotide sequences
of ICAM-1 DNA from the excised tissues were determined
and compared with that reported previously [13]. This
analysis showed no coding changes in CA from rat liver
relative to the consensus sequence. This indicated that
ICAM-1 secreted by the cancer cells was homogeneous
and the cells did not produce a variant molecule. Therefore,
we consider that variant ICAM-1 does not participate in the
progression of the liver fibrosis or hepatocarcinogenesis.
What are the factors which promote the expression of
atypia of hepatocytes in liver? Some factors have been
identified whose serum levels increase in parallel to the
development of F stage in chronic hepatitis and liver
cirrhosis and some factors are present at high levels in
patients with HCC. Such factors include, ICAM-1 [4–6],
human hepatocyte growth factor (HGF) [18, 19], vascular
endothelial growth factor [20] and others. It is thought that
these factors are produced and secreted by hepatoma cells. It
has been confirmed that HGF is expressed by hepatocytes
with strong atypia in our previous studies [21, 22]. In this
study, we also confirm that strong expression of ICAM-1 is
found in hepatocytes with strong atypia, decreased expres-
sion of ICAM-1 is shown in endothelial cells is shown in
AH and small CA. Therefore, it is suggested that ICAM-1 is
produced and secreted by these cells. Although it was not
clear from our present study, we suggest that ICAM-1
influences the development of atypia of hepatocytes by one
of the mechanisms mentioned above.
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